Pre-made Vixtimotamab benchmark antibody ( Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody), anti-CD3E;CD33 therapeutic antibody, Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Vixtimotamab biosimilar, Bispecific Homodimer (VK-VH-VL’-VH’, Tandem diabody)), Anti-CD3E;CD33 Antibody: Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Vixtimotamab biosimilar, Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)), Anti-CD3E;CD33 Antibody: Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 therapeutic antibody |
|---|---|
| INN Name | Vixtimotamab |
| Target | CD3E,CD33 |
| Format | Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody) |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | na;na |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Amphivena Therapeutics |
| Conditions Approved | NA |
| Conditions Active | Acute myeloid leukemia,Myelodysplastic syndromes |
| Conditions Discontinued | NA |
| Development Tech | Tandem diabody |
| Previous Name | NA |
| Gm Offical Target Name | CD3E,CD33 |
| Package |
